{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:25:33Z","timestamp":1793316333619,"version":"4.5.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T00:00:00Z","timestamp":1757376000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.jaad.2025.09.009","type":"journal-article","created":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T02:55:21Z","timestamp":1759200921000},"page":"48-56","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Efficacy and safety of cosibelimab in advanced cutaneous squamous cell carcinoma: Results from a Pivotal Open-label Study with a median follow-up of \u22652 years"],"prefix":"10.1016","volume":"94","author":[{"given":"Emily S.","family":"Ruiz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Mu\u00f1oz-Couselo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henri","family":"Montaudi\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel Angel","family":"Berciano-Guerrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria del Carmen \u00c1lamo","family":"de la Gala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Charles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ga\u00eblle","family":"Qu\u00e9reux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charl\u00e9e","family":"Nardin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo Yaya","family":"Tur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Dalle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Beylot-Barry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul","family":"Ladwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"McGrath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Brungs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dean","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Shue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Tazbirkova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Fourie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel R.","family":"Malan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Oliviero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren Neighbours","family":"Wilcoxen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. Garrett","family":"Gray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Clingan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jaad.2025.09.009_bib1","doi-asserted-by":"crossref","first-page":"377","DOI":"10.3390\/cancers14020377","article-title":"The multidisciplinary management of cutaneous squamous cell carcinoma: a comprehensive review and clinical recommendations by a panel of experts","volume":"14","author":"Stanganelli","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"12","key":"10.1016\/j.jaad.2025.09.009_bib2","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1001\/jamadermatol.2020.3678","article-title":"Underestimation of cutaneous squamous cell carcinoma incidence, even in cancer registries","volume":"156","author":"Wehner","year":"2020","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2025.09.009_bib3","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.733917","article-title":"Immunotherapy for the treatment of cutaneous squamous cell carcinoma","volume":"11","author":"Boutros","year":"2021","journal-title":"Front Oncol"},{"issue":"10","key":"10.1016\/j.jaad.2025.09.009_bib4","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1001\/jamadermatol.2015.1187","article-title":"Incidence estimate of nonmelanoma skin cancer (keratinocyte carcinomas) in the U.S. population, 2012","volume":"151","author":"Rogers","year":"2015","journal-title":"JAMA Dermatol"},{"issue":"11","key":"10.1016\/j.jaad.2025.09.009_bib5","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1001\/jamadermatol.2020.2571","article-title":"Association of age, sex, race, and geographic region with variation of the ratio of basal cell to cutaneous squamous cell carcinomas in the United States","volume":"156","author":"Lukowiak","year":"2020","journal-title":"JAMA Dermatol"},{"issue":"10","key":"10.1016\/j.jaad.2025.09.009_bib8","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007637","article-title":"Efficacy and safety of cosibelimab, an anti-PD-L1 antibody, in metastatic cutaneous squamous cell carcinoma","volume":"11","author":"Clingan","year":"2023","journal-title":"J Immunother Cancer"},{"issue":"6","key":"10.1016\/j.jaad.2025.09.009_bib9","first-page":"69e","article-title":"Treatment of locally advanced and metastatic cutaneous squamous cell carcinoma. Article in Italian","volume":"112","author":"Greco","year":"2021","journal-title":"Recenti Prog Med"},{"issue":"24","key":"10.1016\/j.jaad.2025.09.009_bib10","doi-asserted-by":"crossref","first-page":"6582","DOI":"10.1158\/1078-0432.CCR-14-1768","article-title":"Mutational landscape of aggressive cutaneous squamous cell carcinoma","volume":"20","author":"Pickering","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"25","key":"10.1016\/j.jaad.2025.09.009_bib11","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1056\/NEJMc1713444","article-title":"Tumor mutational burden and response rate to PD-1 inhibition","volume":"377","author":"Yarchoan","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jaad.2025.09.009_bib12","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1186\/s40425-019-0768-9","article-title":"The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors","volume":"7","author":"Davis","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"2","key":"10.1016\/j.jaad.2025.09.009_bib13","doi-asserted-by":"crossref","first-page":"e108","DOI":"10.1111\/ajco.13102","article-title":"Association between PD-L1 expression and lymph node metastasis in cutaneous squamous cell carcinoma","volume":"16","author":"Kamiya","year":"2020","journal-title":"Asia Pac J Clin Oncol"},{"key":"10.1016\/j.jaad.2025.09.009_bib14","series-title":"Regeneron Pharmaceuticals","year":"2021"},{"issue":"1","key":"10.1016\/j.jaad.2025.09.009_bib15","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s12935-021-02407-8","article-title":"Combination therapy with immune checkpoint inhibitors (ICIs): a new frontier","volume":"22","author":"Vafaei","year":"2022","journal-title":"Cancer Cell Int"},{"issue":"7","key":"10.1016\/j.jaad.2025.09.009_bib16","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1001\/jamaoncol.2019.0393","article-title":"Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and meta-analysis","volume":"5","author":"Wang","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jaad.2025.09.009_bib17","article-title":"Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis","volume":"360","author":"Baxi","year":"2018","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.jaad.2025.09.009_bib18","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1002\/cncr.31043","article-title":"Comparison of the toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer: a systematic analysis of the literature","volume":"124","author":"Pillai","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.jaad.2025.09.009_bib19","series-title":"Checkpoint Therapeutics","year":"2024"},{"key":"10.1016\/j.jaad.2025.09.009_bib20","series-title":"Preclinical characterization of a novel fully human IgG1 anti-PD-L1 mAb CK-301","author":"Gorelik","year":"2017"},{"key":"10.1016\/j.jaad.2025.09.009_bib21","series-title":"Semi-mechanistic PK and target-occupancy modeling to support dose justification for anti-PD-L1 clinical candidate CK-301 (cosibelimab) in oncology patients","author":"Lin","year":"2019"},{"issue":"16 suppl","key":"10.1016\/j.jaad.2025.09.009_bib23","doi-asserted-by":"crossref","first-page":"9554","DOI":"10.1200\/JCO.2024.42.16_suppl.9554","article-title":"Pembrolizumab (pembro) for locally advanced (LA) or recurrent\/metastatic (R\/M) cutaneous squamous cell carcinoma (cSCC): long-term results of the phase 2 KEYNOTE-629 study","volume":"42","author":"Couselo","year":"2024","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.jaad.2025.09.009_bib24","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jaad.2024.06.108","article-title":"A phase 2 open-label study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (EMPOWER-CSCC-1): final long-term analysis of groups 1, 2, and 3, and primary analysis of fixed-dose treatment group 6","volume":"92","author":"Hughes","year":"2025","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2025.09.009_bib25","article-title":"Immunotherapy to avoid orbital exenteration in patients with cutaneous squamous cell carcinoma","volume":"11","author":"McLean","year":"2021","journal-title":"Front Oncol"},{"issue":"10","key":"10.1016\/j.jaad.2025.09.009_bib26","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1016\/j.annonc.2021.07.008","article-title":"Pembrolizumab for locally advanced and recurrent\/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial","volume":"32","author":"Hughes","year":"2021","journal-title":"Ann Oncol"},{"issue":"25","key":"10.1016\/j.jaad.2025.09.009_bib27","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.1200\/JCO.19.03054","article-title":"Pembrolizumab monotherapy for recurrent or metastatic cutaneous squamous cell carcinoma: a single-arm phase II trial (KEYNOTE-629)","volume":"38","author":"Grob","year":"2020","journal-title":"J Clin Oncol"},{"issue":"26","key":"10.1016\/j.jaad.2025.09.009_bib28","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1200\/JCO.19.03357","article-title":"Phase II study of pembrolizumab as first-line, single-drug therapy for patients with unresectable cutaneous squamous cell carcinomas","volume":"38","author":"Maubec","year":"2020","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.jaad.2025.09.009_bib29","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/S1470-2045(19)30728-4","article-title":"Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial","volume":"21","author":"Migden","year":"2020","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.jaad.2025.09.009_bib30","doi-asserted-by":"crossref","first-page":"041","DOI":"10.23937\/2474-3631\/1510041","article-title":"Pembrolizumab for locally advanced or recurrent\/metastatic cutaneous squamous cell carcinoma: long-term results of the phase 2 keynote-629 study","volume":"9","author":"Munoz-Couselo","year":"2024","journal-title":"Int Arch Addict Res Med"},{"issue":"1","key":"10.1016\/j.jaad.2025.09.009_bib31","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000775","article-title":"Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing","volume":"8","author":"Rischin","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"5","key":"10.1016\/j.jaad.2025.09.009_bib32","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1084\/jem.20130790","article-title":"RGMb is a novel binding partner for PD-L2 and its engagement with PD-L2 promotes respiratory tolerance","volume":"211","author":"Xiao","year":"2014","journal-title":"J Exp Med"},{"issue":"1","key":"10.1016\/j.jaad.2025.09.009_bib33","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.6879","article-title":"Incidence and risk factors of immune-related adverse events induced by immune checkpoint inhibitors among older adults with non-small cell lung cancer","volume":"13","author":"Rong","year":"2024","journal-title":"Cancer Med"},{"issue":"10","key":"10.1016\/j.jaad.2025.09.009_bib34","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.3390\/cancers16101800","article-title":"Cutaneous squamous cell carcinoma: an updated review","volume":"16","author":"Jiang","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"6","key":"10.1016\/j.jaad.2025.09.009_bib35","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.3390\/cancers15061764","article-title":"Cutaneous squamous cell carcinoma in immunocompromised patients-a comparison between different immunomodulating conditions","volume":"15","author":"Zavdy","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"5","key":"10.1016\/j.jaad.2025.09.009_bib36","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1111\/ijd.15813","article-title":"Cutaneous squamous cell carcinoma in patients with chronic lymphocytic leukemia: a systematic review of the literature","volume":"61","author":"Lai","year":"2022","journal-title":"Int J Dermatol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962225027914?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962225027914?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T13:00:22Z","timestamp":1773147622000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962225027914"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S0190962225027914"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2025.09.009","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of cosibelimab in advanced cutaneous squamous cell carcinoma: Results from a Pivotal Open-label Study with a median follow-up of \u22652 years","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2025.09.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}